Please find enclosed the revised version of the Research Article “Long Pentraxin-3 follows and modulates bladder cancer progression” (Ref: cancers-575172) that I wish to re-submit for publication in Cancers.

In the revised version, we have addressed the Reviewers’ comments (in blue) as detailed below. Changes have been done with track changes in the main text. Moreover “editorial comments” (names of the authors, minor changes in the text of Material and Methods to avoid plagiarism, references’ style) have been implemented.

Reviewer 1.

The only point I might have, is that it would be desirable to have analyzed not three but more cell lines of different grades/molecular subtypes/aggressiveness to achieve more solid data (&gt;=two in each group). However, this does not deteriorate the quality of this excellent work.

We agree with the Reviewer that it could have been interesting to increase the number of cell lines, but the three human cell lines and the murine one, together with the complex in vivo (transgenic and carcinogen- induced) models and data from patients nicely support the conclusions. This aspect would be challenging to reach now, and we appreciate that the Reviewer agree that this is not a mandatory aspect for the assessment of quality of the manuscript.

One minor thing: in line 331, in the discussion section, Erdafitinib has already been approved by the FDA earlier this year for use in the US.

We thank the Reviewer for this clarification. The information has been updated and corrected in the manuscript.

I would like to thank the Reviewers for their comments that have improved the quality of our work. Hoping to have fulfilled the requirements for publication,

I remain yours sincerely,

Dr. Roberto Ronca